Development of PI3K pathway activation status and its application for predicting therapeutic efficacies of PI3-kinase inhibitors

点击翻译按钮获取中文摘要

To explore diagnostic biomarkers for predicting the efficacy of PI3K inhibitors including ZSTK474 that we developed previously, we examined the pathway activation status and the efficacy of PI3K inhibitors in a panel of 39 human cancer cell lines(JFCR39), and constructed an integrated database(DB). Using this DB, we found phospho-Akt and KRAS/BRAF mutation prominently correlated with the efficacy and the inefficacy of PI3K inhibitors, respectively. These correlations were confirmed in human tumor xenografts in vivo, suggesting that they could serve as predictive biomarkers in future clinical trials.